MYT1L Syndrome: a Rare Paediatric Genetic Syndrome Responsible for a Neurodevelopmental Disorder
Recruiting
N/A
Interventional Study
MYT1L Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 6 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- University Hospital, Rouen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
MYT1L syndrome is a rare genetic syndrome, recently described in 2011, with paediatric onset, responsible for a neurodevelopmental disorder combining psychomotor retardation, learning difficulties and/or intellectual development disorders, epilepsy, overweight and eating disorders. The Rouen genetics department is currently positioned as a clinical expert in this disease.
The study published in 2…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
MYT1L Group Patients
* Minimum age for inclusion: 6 years
* Maximum age for inclusion: no upper age limit
* Language: French
* Consent of parents or legal guardian
* Social security coverage required
Prosody Group Patients
* Unaided visual or hearing impairment making assessm…
Contacts